Patent · US Active

Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

US11684671B2 · kind B2 · utility

0Cited by

4References

8Claims

0Family size

Assignee

VRIJE UNIVERSITEIT BRUSSEL · BE

Inventors

Kris Thielemans · Wilrijk, BE
Aude Bonehill · Essene, BE

Key dates

Filing date	Mar 29, 2019
Grant date	Jun 27, 2023
Priority date	—
Expiry date	May 30, 2039

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TI R4 (caTIR4).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.